APA (7th ed.) Citation

Aslan, B., Kismali, G., Iles, L. R., Manyam, G. C., Ayres, M. L., Chen, L. S., . . . Gandhi, V. (2022). Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood cancer journal (New York), 12(5), 80-12. https://doi.org/10.1038/s41408-022-00675-9

Chicago Style (17th ed.) Citation

Aslan, Burcu, et al. "Pirtobrutinib Inhibits Wild-type and Mutant Bruton’s Tyrosine Kinase-mediated Signaling in Chronic Lymphocytic Leukemia." Blood Cancer Journal (New York) 12, no. 5 (2022): 80-12. https://doi.org/10.1038/s41408-022-00675-9.

MLA (9th ed.) Citation

Aslan, Burcu, et al. "Pirtobrutinib Inhibits Wild-type and Mutant Bruton’s Tyrosine Kinase-mediated Signaling in Chronic Lymphocytic Leukemia." Blood Cancer Journal (New York), vol. 12, no. 5, 2022, pp. 80-12, https://doi.org/10.1038/s41408-022-00675-9.